Diabetic Nephropathy - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 220
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DFA92E5C46DEN
Leaflet:

Download PDF Leaflet

Diabetic Nephropathy - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2016’, provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
  • The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Diabetic Nephropathy Overview
Therapeutics Development
Pipeline Products for Diabetic Nephropathy - Overview
Pipeline Products for Diabetic Nephropathy - Comparative Analysis
Diabetic Nephropathy - Therapeutics under Development by Companies
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Nephropathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Diabetic Nephropathy - Products under Development by Companies
Diabetic Nephropathy - Products under Investigation by Universities/Institutes
Diabetic Nephropathy - Companies Involved in Therapeutics Development
AbbVie Inc
Ampio Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Araim Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Cellmid Limited
ChemoCentryx, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Dimerix Bioscience Pty Ltd
Dong Wha Pharma Co., Ltd.
Dynamis Therapeutics, Inc.
Eli Lilly and Company
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Glucox Biotech AB
GNI Group Ltd.
Islet Sciences, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Mallinckrodt Plc
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
MorphoSys AG
Noxxon Pharma AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
PhytoHealth Corporation
ProMetic Life Sciences Inc.
Serodus ASA
Takeda Pharmaceutical Company Limited
Theravance Biopharma, Inc.
Tobira Therapeutics, Inc.
Vascular Pharmaceuticals, Inc.
Vicore Pharma AB
Diabetic Nephropathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
11-RVIVIT - DRUG PROFILE
A-717 - Drug Profile
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
APD-371 - Drug Profile
APX-115 - Drug Profile
ASP-8232 - Drug Profile
ATL-1103 - Drug Profile
atrasentan hydrochloride - Drug Profile
baricitinib - Drug Profile
BI-703704 - Drug Profile
BOT-191 - Drug Profile
C-21 - Drug Profile
canagliflozin - Drug Profile
CCX-140 - Drug Profile
cenicriviroc mesylate - Drug Profile
cibinetide - Drug Profile
corticotropin - Drug Profile
CS-3150 - Drug Profile
CSL-346 - Drug Profile
Cyndacel-M - Drug Profile
danazol - Drug Profile
DMX-250 - Drug Profile
DT-23552 - Drug Profile
DW-1029M - Drug Profile
DYN-12 - Drug Profile
emapticap pegol - Drug Profile
finerenone - Drug Profile
GKT-136901 - Drug Profile
GKT-831 - Drug Profile
GRMD-02 - Drug Profile
GW-610742 - Drug Profile
IP-9 - Drug Profile
JD-5037 - Drug Profile
JNJ-39933673 - Drug Profile
MG-132 - Drug Profile
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile
MOR-107 - Drug Profile
MPC-300IV - Drug Profile
MT-3995 - Drug Profile
Nephrilin - Drug Profile
Orbcel-M - Drug Profile
oxypurinol - Drug Profile
PBI-4050 - Drug Profile
PBI-4547 - Drug Profile
PHN-033 - Drug Profile
pirfenidone - Drug Profile
probucol - Drug Profile
selonsertib - Drug Profile
SER-150 - Drug Profile
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile
Small Molecules for Diabetic Nephropathy - Drug Profile
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
SP-20202 - Drug Profile
TAK-272 - Drug Profile
TBE-31 - Drug Profile
TD-0714 - Drug Profile
VPI-2690B - Drug Profile
VS-105 - Drug Profile
XRX-108 - Drug Profile
XRX-221 - Drug Profile
Diabetic Nephropathy - Dormant Projects
Diabetic Nephropathy - Discontinued Products
Diabetic Nephropathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Nephropathy, H2 2016
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2016
Diabetic Nephropathy - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H2 2016
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H2 2016
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2016
Diabetic Nephropathy - Pipeline by Bayer AG, H2 2016
Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H2 2016
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Diabetic Nephropathy - Pipeline by Cellmid Limited, H2 2016
Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H2 2016
Diabetic Nephropathy - Pipeline by CSL Limited, H2 2016
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H2 2016
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H2 2016
Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H2 2016
Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H2 2016
Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H2 2016
Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H2 2016
Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H2 2016
Diabetic Nephropathy - Pipeline by GNI Group Ltd., H2 2016
Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2016
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H2 2016
Diabetic Nephropathy - Pipeline by Mesoblast Limited, H2 2016
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2016
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2016
Diabetic Nephropathy - Pipeline by Omeros Corporation, H2 2016
Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H2 2016
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H2 2016
Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2016
Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Diabetic Nephropathy - Pipeline by Theravance Biopharma, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2016
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Nephropathy - Dormant Projects, H2 2016
Diabetic Nephropathy - Dormant Projects (Contd.1), H2 2016
Diabetic Nephropathy - Dormant Projects (Contd.2), H2 2016
Diabetic Nephropathy - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Diabetic Nephropathy, H2 2016
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

AbbVie Inc
Ampio Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Araim Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Cellmid Limited
ChemoCentryx, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Dimerix Bioscience Pty Ltd
Dong Wha Pharma Co., Ltd.
Dynamis Therapeutics, Inc.
Eli Lilly and Company
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Glucox Biotech AB
GNI Group Ltd.
Islet Sciences, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Mallinckrodt Plc
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
MorphoSys AG
Noxxon Pharma AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
PhytoHealth Corporation
ProMetic Life Sciences Inc.
Serodus ASA
Takeda Pharmaceutical Company Limited
Theravance Biopharma, Inc.
Tobira Therapeutics, Inc.
Vascular Pharmaceuticals, Inc.
Vicore Pharma AB
Skip to top


Nephropathy - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 59 pages
Nephropathy - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 57 pages
Diabetic Nephropathy - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Diabetic Nephropathy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: